- Jim Spencer promoted to president of Kinney Drugs stores
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- CVS Caremark's Merlo attends reception to accept March of Dimes Citizen of the Year award
- Senate passes Drug Quality and Security Act
- Countdown to McKesson ideaShare 2013: MiS to compile best thinking, new ideas for independent pharmacy
IRVINE, Calif. — Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.
The changeover takes place March 27.
“[Ball] has continuously made significant contributions to the success of Allergan during his 16 years of service and has been a key partner since I arrived in January 1998,” stated Pyott. “His appointment as chief executive officer of Hospira is a testament to his many skills and his leadership capabilities. We wish him much success in the next stage of his career.”
Pyott’s role as president is not an interim position as Allergan does not currently plan to name a new president, the company reported.